

Reference Number: FOI202122395
From: Commercial
Date: 09 December 2021
Subject: incidence and treatment of Haemophilia A

Q1 In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

A1 This is for patients on these treatments September to November 2021.
We have 45 patients on prophylaxis but an extra 3 on Refacto, who, although not on prophylaxis, were treated in this time period for bleeds.

Of those

Advate = 3

Adynovi = 0

Elocta = 5

Esperoct = 0

FEIBA = 1

Hemlibra = 25

Novoeight = 8

Novoseven = 0

Refacto = 6

Total is 48.

Q2 In the last three months, how many patients were treated with the following products for mild Haemophilia A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

A2 Advate = 0

Adynovi = 0
Elocta = 2
Esperoct = 0
Factor Eight Inhibitor Bypass Activity (FEIBA) = 0
Hemlibra = 0
Novoeight = 0
Novoseven = 0
Refacto = 2 for bleeds

Total = 4

Q3 For patients treated with Hemlibra in the last three months, please provide

- The number of haemophilia A patients with inhibitors
- The number of mild haemophilia A patients with inhibitors

A3 No. of Haem A patients with an inhibitor = 0

No. of mild Haem A patients with an inhibitor = 0

Q4 How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.

A4 68